<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id><journal-id journal-id-type="publisher-id">IRV</journal-id><journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title></journal-title-group><issn pub-type="ppub">1750-2640</issn><issn pub-type="epub">1750-2659</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20409210</article-id><article-id pub-id-type="pmc">4941661</article-id><article-id pub-id-type="doi">10.1111/j.1750-2659.2009.00124.x</article-id><article-id pub-id-type="publisher-id">IRV124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Efficacy of live attenuated influenza vaccine in children 6&#x02003;months to 17&#x02003;years of age</article-title><alt-title alt-title-type="left-running-head">Belshe <italic>et&#x000a0;al.</italic></alt-title><alt-title alt-title-type="right-running-head">Efficacy of LAIV by age</alt-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name><surname>Belshe</surname><given-names>Robert B.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name><surname>Toback</surname><given-names>Seth L.</given-names></name><xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Yi</surname><given-names>Tingting</given-names></name><xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Ambrose</surname><given-names>Christopher S.</given-names></name><xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="a1"><label><sup>1</sup></label>Saint Louis University Health Science Center, St Louis, MO, USA</aff><aff id="a2"><label><sup>2</sup></label>MedImmune, One MedImmune Way, Gaithersburg, MD, USA</aff><author-notes><corresp id="correspondenceTo">Robert B. Belshe, MD, Saint Louis University School of Medicine, 1100 S. Grand Blvd., DRC&#x02010;8th Floor, St Louis, MO 63104, USA.&#x02028;E&#x02010;mail: <email>belsherb@slu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2010</year></pub-date><volume>4</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/irv.2010.4.issue-3</issue-id><fpage>141</fpage><lpage>145</lpage><history>
Accepted 12 December 2009. Published Online 2 February 2010.</history><permissions><copyright-statement content-type="article-copyright">&#x000a9; 2010 Blackwell Publishing Ltd</copyright-statement></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IRV-4-141.pdf"/><abstract><p>
<italic>Please cite this paper as:</italic> Belshe <italic>et al.</italic> (2010). Efficacy of live attenuated influenza vaccine in children 6&#x02003;months to 17&#x02003;years of age. Influenza and Other Respiratory Viruses 4(3), 141&#x02013;145.</p><p>
<bold>Background&#x02002;</bold> It has been suggested that live attenuated influenza vaccine (LAIV) may be less effective in older individuals because of prior wild&#x02010;type influenza infections. LAIV is currently approved in the United States, South Korea and Hong Kong for individuals 2&#x02013;49&#x02003;years of age.</p><p>
<bold>Objective&#x02002;</bold> To examine data from previously published pediatric studies to determine the efficacy of LAIV in various age groups.</p><p>
<bold>Methods&#x02002;</bold> Four studies in which the subject age range exceeded 36&#x02003;months were identified: one 2&#x02010;year study comparing LAIV with placebo and three 1&#x02010;year studies comparing LAIV with trivalent inactivated influenza vaccine (TIV). Efficacy against any strain regardless of antigenic similarity to vaccine was analyzed by age; age groups were based on the study design and sample size. A logistic regression model was used to assess whether age, as a continuous variable, was an effect modifier on LAIV efficacy.</p><p>
<bold>Results&#x02002;</bold> The efficacy of LAIV did not vary with age in children aged 15&#x02013;84&#x02003;months compared with placebo or in children aged 6&#x02003;months to 17&#x02003;years compared with TIV.</p><p>
<bold>Conclusions&#x02002;</bold> The available data from prospective, randomized studies in children does not support the concept that prior repeated exposure to influenza, either through wild&#x02010;type infection or vaccination with live, attenuated or inactivated vaccines, reduces the efficacy of LAIV compared with placebo or TIV. The decreased immunologic responses to LAIV reported in older individuals or those with pre&#x02010;existing immunity do not appear to translate into reduced protection from influenza in children.</p></abstract><kwd-group><kwd id="k1">Influenza</kwd><kwd id="k2">live attenuated influenza vaccine</kwd><kwd id="k3">trivalent&#x02010;inactivated influenza vaccine</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2010</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="ss1"><title>Introduction</title><p>Multiple prospective, randomized, controlled studies have described the efficacy of live attenuated influenza vaccine (LAIV) in children and adolescents compared with placebo and with trivalent inactivated influenza vaccine (TIV).<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="b2" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref>, <xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="b5" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="b6" ref-type="ref">
<sup>6</sup>
</xref>, <xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="b8" ref-type="ref">
<sup>8</sup>
</xref>, <xref rid="b9" ref-type="ref">
<sup>9</sup>
</xref>, <xref rid="b10" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="b11" ref-type="ref">
<sup>11</sup>
</xref> LAIV provided levels of efficacy against influenza illness that, in the three comparative studies conducted, were significantly higher than those provided by TIV.<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref>, <xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref> In contrast, comparative studies in adults &#x02265;18&#x02003;years of age have demonstrated variable results; studies have demonstrated comparable protection of the two vaccines,<xref rid="b12" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="b13" ref-type="ref">
<sup>13</sup>
</xref>, <xref rid="b14" ref-type="ref">
<sup>14</sup>
</xref>, <xref rid="b15" ref-type="ref">
<sup>15</sup>
</xref>, <xref rid="b16" ref-type="ref">
<sup>16</sup>
</xref> greater protection with TIV,<xref rid="b17" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="b18" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref> and, in some cases, greater protection with LAIV.<xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref> For studies that have demonstrated greater protection with TIV in adults, authors have speculated that LAIV may be less effective in older individuals because of prior infections with similar wild&#x02010;type influenza strains.<xref rid="b15" ref-type="ref">
<sup>15</sup>
</xref>, <xref rid="b17" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="b18" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref>
</p><p>Of the previously conducted studies of LAIV efficacy, only two analyzed efficacy by age group, and neither suggested a reduction in effectiveness of LAIV in children with increasing age.<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref> The purpose of the present analysis is to more fully explore the efficacy of LAIV by age group based on data from previously conducted studies.</p><p>Studies comparing the safety of LAIV and TIV have demonstrated comparable safety in individuals 2&#x02003;years of age and older. In one study,<xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref> among children 6&#x02013;23&#x02003;months of age, an increased rate of wheezing through 6&#x02003;weeks following vaccination was associated with LAIV (5&#x000b7;9% LAIV versus 3&#x000b7;8% TIV); however, no increase was among children 24&#x02013;59&#x02003;months of age. LAIV is currently approved for use in the United States, South Korea and Hong Kong for the active immunization of eligible individuals 2&#x02013;49&#x02003;years of age against influenza.</p></sec><sec id="ss2"><title>Materials and methods</title><p>From a review of all available studies, only four LAIV efficacy studies in which the subject age range exceeded 36&#x02003;months were identified for this <italic>post hoc</italic> analysis (<xref rid="t1" ref-type="table-wrap">Table&#x000a0;1</xref>): one 2&#x02010;year study of efficacy comparing LAIV to placebo and three 1&#x02010;year studies comparing LAIV with TIV [the studies were conducted by Aviron, Inc., Mountain View, CA, USA (now MedImmune) and Wyeth Research, Pearl River, NY, USA].<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref>, <xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="b5" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref> In all studies, efficacy against any strain regardless of antigenic similarity to vaccine was analyzed. Age groups for analysis were defined based on the study design and sample size. The placebo&#x02010;controlled study (study 1<xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="b5" ref-type="ref">
<sup>5</sup>
</xref>) allowed meaningful analysis of smaller subgroups, and 12&#x02010;month cohorts were used. In the TIV&#x02010;controlled studies (studies 2<xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref>, 3<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref> and 4<xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref>), larger age cohorts were used as needed based on the study sample size. The large size of study 2 permitted 12&#x02010;month cohort analysis, but studies 3 and 4 were smaller, and children above and below the midpoint of the enrollment age range were analyzed. Where available (study 1), additional data on pre&#x02010;vaccination antibody levels were also analyzed by age group to better understand pre&#x02010;existing anti&#x02010;influenza immunity in the study population. Baseline pre&#x02010;vaccination serum antibody levels were evaluated in a small cohort of children (<italic>n</italic>&#x02003;=&#x02003;203); subjects with a hemagglutinin inhibition titer &#x02264;4 were considered seronegative, whereas those with a hemagglutinin inhibition titer of &#x02265;8 were considered seropositive.</p><table-wrap id="t1" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>&#x02002;Study characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="left" valign="bottom" rowspan="1" colspan="1">Influenza season</th><th align="left" valign="bottom" rowspan="1" colspan="1">Age at enrollment</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control</th><th align="left" valign="bottom" rowspan="1" colspan="1">Geographic location</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1, year 1, Belshe</td><td align="left" valign="top" rowspan="1" colspan="1">1996&#x02013;1997</td><td align="left" valign="top" rowspan="1" colspan="1">15&#x02013;71&#x02003;months</td><td align="left" valign="top" rowspan="1" colspan="1">1602</td><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1, year 2, Belshe</td><td align="left" valign="top" rowspan="1" colspan="1">1997&#x02013;1998</td><td align="left" valign="top" rowspan="1" colspan="1">27&#x02013;83&#x02003;months</td><td align="left" valign="top" rowspan="1" colspan="1">1358</td><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2, Belshe</td><td align="left" valign="top" rowspan="1" colspan="1">2004&#x02013;2005</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;6&#x02013;59&#x02003;months</td><td align="left" valign="top" rowspan="1" colspan="1">7852</td><td align="left" valign="top" rowspan="1" colspan="1">TIV</td><td align="left" valign="top" rowspan="1" colspan="1">Global</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3, Ashkenazi</td><td align="left" valign="top" rowspan="1" colspan="1">2002&#x02013;2003</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;6&#x02013;71&#x02003;months</td><td align="left" valign="top" rowspan="1" colspan="1">2085</td><td align="left" valign="top" rowspan="1" colspan="1">TIV</td><td align="left" valign="top" rowspan="1" colspan="1">Europe/Israel</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4, Fleming</td><td align="left" valign="top" rowspan="1" colspan="1">2002&#x02013;2003</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;6&#x02013;17&#x02003;years</td><td align="left" valign="top" rowspan="1" colspan="1">2202</td><td align="left" valign="top" rowspan="1" colspan="1">TIV</td><td align="left" valign="top" rowspan="1" colspan="1">Europe/Israel</td></tr></tbody></table><table-wrap-foot><fn id="t1_note36"><p>LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.</p></fn></table-wrap-foot></table-wrap><p>Study 1 was a 2&#x02010;year, multicenter, prospective, double&#x02010;blind trial conducted in the United States during the 1996&#x02013;1998 influenza seasons in previously unvaccinated children 15&#x02013;71&#x02003;months of age.<xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="b5" ref-type="ref">
<sup>5</sup>
</xref> The efficacy of LAIV was analyzed for children 15&#x02013;23&#x02003;months, 24&#x02013;35&#x02003;months, 36&#x02013;47&#x02003;months, 48&#x02013;59&#x02003;months and &#x02265;60&#x02003;months of age. Study 2 was a multinational, double&#x02010;blind, head&#x02010;to&#x02010;head trial conducted during the 2004&#x02013;2005 influenza season in children 6&#x02013;59&#x02003;months of age.<xref rid="b3" ref-type="ref">
<sup>3</sup>
</xref> Efficacy of LAIV compared with TIV was analyzed for children 6&#x02013;23&#x02003;months, 24&#x02013;35&#x02003;months, 36&#x02013;47&#x02003;months and 48&#x02013;59&#x02003;months of age. Studies 3 and 4 were randomized, open&#x02010;label studies conducted in Europe and Israel during the 2002&#x02013;2003 influenza season of two doses of vaccine in children 6&#x02013;71&#x02003;months of age with recurrent respiratory tract infections and one dose of vaccine in children and adolescents 6&#x02013;17&#x02003;years of age with medically stable asthma, respectively.<xref rid="b1" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="b7" ref-type="ref">
<sup>7</sup>
</xref> Efficacy of LAIV compared with TIV was analyzed for children aged 6&#x02013;35 and 36&#x02013;71&#x02003;months for study 3 and aged 6&#x02013;11 and 12&#x02013;17&#x02003;years of age for study 4. All studies contacted subjects weekly throughout the influenza season and calculated efficacy based on the incidence of culture&#x02010;confirmed influenza illness.</p><p>In addition to the categorical age group analysis, a logistic regression model for each study was used to assess whether age, as a continuous variable, was an effect modifier on LAIV efficacy. The model used culture&#x02010;confirmed influenza illness as the dependent variable. Independent variables included treatment group, age as a continuous variable and the interaction between age and treatment. The interaction term was tested for significance to assess the impact of age on LAIV efficacy.</p></sec><sec id="ss3"><title>Results</title><p>In study 1, efficacy against all strains regardless of match to strains contained in the vaccine in year 1 ranged from 85 to 100% across the age cohorts analyzed, and there was no decrease with increasing age (<xref rid="t2" ref-type="table-wrap">Table&#x000a0;2</xref>). Similarly, after revaccination in year 2, efficacy did not vary by age, ranging from 84 to 92%. In the subset of subjects tested, baseline seropositivity increased with increasing age (<xref rid="f1" ref-type="fig">Figure&#x000a0;1</xref>). In the youngest age group, 73 to 87% of subjects were seronegative to the vaccine strains, whereas in the oldest age group only 33 to 58% were seronegative. Baseline geometric mean titers also generally increased with increasing age (<xref rid="f2" ref-type="fig">Figure&#x000a0;2</xref>); 8&#x000b7;9%, 12&#x000b7;5%, 11&#x000b7;4%, 18&#x000b7;9% and 18&#x000b7;5% of subjects aged 15&#x02013;23, 24&#x02013;35, 36&#x02013;47, 48&#x02013;59 and &#x02265;60&#x02003;months, respectively, had a baseline antibody titer &#x0003e;1:40.</p><table-wrap id="t2" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>&#x02002;Efficacy of LAIV versus placebo by age and strain (study 1, years 1 and 2)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" valign="bottom" align="left" colspan="1">Age, months (<italic>n</italic>)*</th><th rowspan="3" valign="bottom" align="left" colspan="1">All strains**&#x02028;Efficacy, % (95% CI)</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">H3N2**</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">B**</th></tr><tr><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Efficacy, % (95% CI)</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Efficacy, % (95% CI)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" rowspan="1">Year 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;15&#x02013;23 (272)</td><td align="left" valign="top" rowspan="1" colspan="1">85 (58&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">90 (59&#x02013;97)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">71 (&#x02212;32 to 94)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;24&#x02013;35 (359)</td><td align="left" valign="top" rowspan="1" colspan="1">96 (86&#x02013;99)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">15&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">94 (79&#x02013;99)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">9&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">100 (81&#x02013;100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;36&#x02013;47 (327)</td><td align="left" valign="top" rowspan="1" colspan="1">87 (67&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">89 (63&#x02013;97)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">83 (27&#x02013;96)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;48&#x02013;59 (332)</td><td align="left" valign="top" rowspan="1" colspan="1">100 (90&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">100 (85&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">7&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">100 (77&#x02013;100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;60 (312)</td><td align="left" valign="top" rowspan="1" colspan="1">91 (70&#x02013;97)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;8&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">100 (79&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">8&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">84 (44&#x02013;95)</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">2Year 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;27&#x02013;35 (246)</td><td align="left" valign="top" rowspan="1" colspan="1">84 (35&#x02013;96)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02002;8&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">84 (35&#x02013;96)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;36&#x02013;47 (294)</td><td align="left" valign="top" rowspan="1" colspan="1">85 (57&#x02013;94)</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">13&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">85 (57&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;48&#x02013;59 (274)</td><td align="left" valign="top" rowspan="1" colspan="1">92 (69&#x02013;98)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">91 (65&#x02013;98)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">100 (&#x02212;50 to 100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003e;60 (544)</td><td align="left" valign="top" rowspan="1" colspan="1">87 (71&#x02013;94)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">14&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">87 (71&#x02013;94)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="t2_note86"><p>LAIV, live attenuated influenza vaccine; NA, not applicable.</p></fn><fn id="t2_note87"><p>*Age strata in initial year of vaccination.</p></fn><fn id="t2_note88"><p>**Regardless of antigenic match to vaccine. Influenza A/H1N1 did not circulate during the study and was not isolated.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>&#x02002;Baseline seronegativity by age and strain (study 1, year 1; <italic>n</italic>&#x02003;=&#x02003;203).</p></caption><graphic id="nlm-graphic-1" xlink:href="IRV-4-141-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>&#x02002;Baseline geometric mean titers (95% CI) by age and strain (study 1, year 1; <italic>n</italic>&#x02003;=&#x02003;203).</p></caption><graphic id="nlm-graphic-3" xlink:href="IRV-4-141-g002"/></fig><p>In the first of the three TIV&#x02010;controlled studies, study 2, the relative efficacy of LAIV compared with TIV against all strains regardless of match ranged from 42 to 57% and was similar regardless of age (<xref rid="t3" ref-type="table-wrap">Table&#x000a0;3</xref>). Studies 3 and 4 similarly showed no decline in efficacy with increasing age (<xref rid="t4" ref-type="table-wrap">Table&#x000a0;4</xref>). In study 3, a trend showing higher relative efficacy of LAIV compared with TIV was seen in subjects 36&#x02013;71&#x02003;months of age compared with those 6&#x02013;35&#x02003;months of age, but this trend was because of the differential incidence of A/H3N2 versus A/H1N1 and B in the two age strata; analyzed by strain, the relative efficacy in each age group was similar. In all studies, efficacy against individual strains should be interpreted with caution because of the low number of influenza cases in some comparisons.</p><table-wrap id="t3" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>&#x02002;Relative efficacy of LAIV versus TIV by age and strain (study 2)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" valign="bottom" align="left" colspan="1">Age, months (<italic>n</italic>)</th><th rowspan="3" valign="bottom" align="left" colspan="1">All strains*&#x02028;Relative efficacy, % (95% CI)</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">H1N1*</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">H3N2*</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">B*</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">6&#x02013;23 (3686)</td><td align="left" valign="top" rowspan="1" colspan="1">56 (40&#x02013;68)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">67 (&#x02212;56 to 95)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">83 (70&#x02013;91)</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">15 (&#x02212;29 to 43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24&#x02013;35 (2612)</td><td align="left" valign="top" rowspan="1" colspan="1">57 (40&#x02013;69)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">78 (&#x02212;79 to 99)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">82 (68&#x02013;90)</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">10 (&#x02212;42 to 43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36&#x02013;47 (846)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (5&#x02013;66)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">100 (63&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;4</td><td align="left" valign="top" rowspan="1" colspan="1">48 (&#x02212;29 to 81)</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">12 (&#x02212;69 to 55)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">48&#x02013;59 (708)</td><td align="left" valign="top" rowspan="1" colspan="1">56 (25&#x02013;75)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">100 (47&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">76 (22&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">7&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">25 (&#x02212;37 to 60)</td></tr></tbody></table><table-wrap-foot><fn id="t3_note61"><p>LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.</p></fn><fn id="t3_note62"><p>*Regardless of antigenic match to vaccine.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>&#x02002;Relative efficacy of LAIV versus TIV age and strain (studies 3 and 4)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" valign="bottom" align="left" colspan="1">Study</th><th rowspan="3" valign="bottom" align="left" colspan="1">Age (<italic>n</italic>)</th><th rowspan="3" valign="bottom" align="left" colspan="1">All strains*&#x02028;Relative efficacy, % (95% CI)</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">H1N1*</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">H3N2*</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">B*</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Attack rate, %</th><th rowspan="2" valign="bottom" align="left" colspan="1">Relative efficacy, % (95% CI)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">LAIV</th><th align="left" valign="bottom" rowspan="1" colspan="1">TIV</th></tr></thead><tbody valign="top"><tr><td rowspan="2" valign="top" align="left" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">6&#x02013;35&#x02003;months (952)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (&#x02212;30 to 64)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">100 (1&#x02013;100)</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;47 (&#x02212;309 to 44)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;2</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">55 (&#x02212;30 to 86)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3&#x02013;6&#x02003;years (1133)</td><td align="left" valign="top" rowspan="1" colspan="1">70 (38&#x02013;87)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">100 (&#x02212;16 to 100)</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;33 (&#x02212;568 to 72)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;1</td><td align="left" valign="top" rowspan="1" colspan="1">4&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">76 (39&#x02013;92)</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">4**</td><td align="left" valign="top" rowspan="1" colspan="1">6&#x02013;11&#x02003;years (1376)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (&#x02212;8 to 57)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">100 (&#x02212;62 to 100)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;0</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;53 (&#x02212;373 to 48)</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;8</td><td align="left" valign="top" rowspan="1" colspan="1">5&#x000b7;9</td><td align="left" valign="top" rowspan="1" colspan="1">36 (&#x02212;7 to 63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12&#x02013;17&#x02003;years (835)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (&#x02212;43 to 66)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">100 (&#x02212;369 to 100)</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;6</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x000b7;5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3 (&#x02212;270 to 70)</td><td align="left" valign="top" rowspan="1" colspan="1">2&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x000b7;3</td><td align="left" valign="top" rowspan="1" colspan="1">32 (&#x02212;67 to 73)</td></tr></tbody></table><table-wrap-foot><fn id="t4_note64"><p>LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.</p></fn><fn id="t4_note65"><p>*Regardless of antigenic match to vaccine.</p></fn><fn id="t4_note66"><p>**Conducted in children with stable, medically treated asthma, a population for whom there is a warning/precaution against the use of LAIV.</p></fn></table-wrap-foot></table-wrap><p>The results of the logistic regression model were consistent with those seen with the age group analysis. Age was not significantly correlated with vaccine efficacy in study 1&#x02003;year 1, study 1&#x02003;year 2, study 2, or study 4 (<italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;55, 0&#x000b7;99, 0&#x000b7;93, 0&#x000b7;17, respectively). For study 3, vaccine efficacy increased slightly with age (<italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;03); however, strain&#x02010;specific efficacy was not correlated for any of the strains (<italic>P&#x02003;</italic>=<italic>&#x02003;</italic>0&#x000b7;99, 0&#x000b7;57 and 0&#x000b7;11 for A/H1N1, A/H3N2 and B, respectively).</p></sec><sec id="ss4"><title>Discussion</title><p>The data presented here in children and adolescents spanning a range of 17&#x000b7;5&#x02003;years does not support the hypothesis that the efficacy of LAIV declines with increasing age. In study 1, as would be expected, a greater proportion of previously unvaccinated older children had pre&#x02010;existing serum antibody to the vaccine strains, reflecting increased previous natural infection with antigenically related viruses. Nevertheless, vaccine efficacy was equally high for older children and younger children, and thus there was no suggestion that increasing levels of pre&#x02010;existing anti&#x02010;influenza immunity influenced LAIV efficacy. Data presented here and elsewhere<xref rid="b2" ref-type="ref">
<sup>2</sup>
</xref> also suggest that LAIV efficacy does not decline in those previously vaccinated with LAIV; in fact, a trend toward increased efficacy with revaccination has been reported in a meta&#x02010;analysis of four 2&#x02010;year studies in children younger than 7&#x02003;years of age.<xref rid="b2" ref-type="ref">
<sup>2</sup>
</xref> Prior vaccination with TIV has also not been shown to impact LAIV efficacy relative to TIV; specifically, in study 2, the relative efficacy of LAIV compared with TIV against all strains regardless of antigenic match was similar in children aged 6&#x02013;59&#x02003;months who were previously vaccinated with TIV (51%) and those previously unvaccinated (57%).<xref rid="b20" ref-type="ref">
<sup>20</sup>
</xref> Accordingly, the available data from these prospective, randomized studies in children does not support the hypothesis that prior repeated exposure to influenza, either through wild&#x02010;type infection or vaccination with live, attenuated or inactivated vaccines, may reduce the efficacy of LAIV compared with placebo or TIV. This conclusion is also supported by the observation that LAIV retained its effectiveness in a consecutive multiseason open&#x02010;label study of 6569 children in which 50% of those in the study had received 1 or more doses of LAIV in the preceding 3&#x02003;years of the study.<xref rid="b21" ref-type="ref">
<sup>21</sup>
</xref>
</p><p>The finding that the protection provided by LAIV does not decline with age, prior vaccination or pre&#x02010;existing anti&#x02010;influenza antibody is somewhat counter&#x02010;intuitive given that immunologic responses to LAIV do decline in those with greater prior immunity to influenza. In children, serum antibody responses and shedding of LAIV vaccine strains have both been shown to decrease with increasing age, increasing baseline serum antibody levels and prior vaccination with LAIV.<xref rid="b4" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="b22" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="b23" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="b24" ref-type="ref">
<sup>24</sup>
</xref> Although achieving an HAI titer of 1:40 is generally considered a correlate of approximately 50% protection for inactivated influenza vaccines,<xref rid="b25" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="b26" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="b27" ref-type="ref">
<sup>27</sup>
</xref> there is no established correlate of protection for LAIV. As a result, predicting the precise level of protection provided in specific subpopulations is not possible; however, the available data suggest that the above&#x02010;referenced age&#x02010;based differences in immunologic responses do not translate into reduced protection from influenza.</p><p>The only prospective, randomized study demonstrating a statistically significant reduction in efficacy with LAIV relative to TIV in adults was an open&#x02010;label study conducted on university campuses in Michigan;<xref rid="b17" ref-type="ref">
<sup>17</sup>
</xref> this finding should be explored in additional studies in other settings. It is possible that variations in study endpoint and population, and season&#x02010;to&#x02010;season variability may contribute to the conflicting results regarding the relative efficacy of LAIV and TIV in adults.<xref rid="b14" ref-type="ref">
<sup>14</sup>
</xref>, <xref rid="b19" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="b28" ref-type="ref">
<sup>28</sup>
</xref> In the more robust pediatric data, there is evidence to suggest that LAIV efficacy does not decline with increasing age. More research on influenza vaccination is needed to describe the efficacy of LAIV and TIV in older adolescents and adults. A large comparative study with a sample size in the range of 24&#x02003;000 subjects may be required to answer such a question.</p></sec><sec id="ss6"><title>Acknowledgement</title><p>This study was sponsored by MedImmune, LLC, Gaithersburg, MD.</p></sec></body><back><ack id="ss5"><title>Conflict of Interest</title><p>Chris Ambrose, Tingting Yi, and Seth Toback are currently employees of MedImmune, LLC and as such receives a salary from the company.</p></ack><ref-list id="ss7"><title>References</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1">
<string-name>
<surname>Ashkenazi</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Vertruyen</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Aristegui</surname>
<given-names>J</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections</article-title>. 
<source>Pediatr Infect Dis J</source>
<year>2006</year>; <volume>25</volume>:<fpage>870</fpage>&#x02013;<lpage>879</lpage>.
<pub-id pub-id-type="pmid">17006279</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2">
<string-name>
<surname>Rhorer</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Ambrose</surname>
<given-names>CS</given-names>
</string-name>, 
<string-name>
<surname>Dickinson</surname>
<given-names>S</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Efficacy of live attenuated influenza vaccine in children: a meta&#x02010;analysis of nine randomized clinical trials</article-title>. 
<source>Vaccine</source>
<year>2009</year>; <volume>27</volume>:<fpage>1101</fpage>&#x02013;<lpage>1110</lpage>.
<pub-id pub-id-type="pmid">19095024</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3">
<string-name>
<surname>Belshe</surname>
<given-names>RB</given-names>
</string-name>, 
<string-name>
<surname>Edwards</surname>
<given-names>KM</given-names>
</string-name>, 
<string-name>
<surname>Vesikari</surname>
<given-names>T</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Live attenuated versus inactivated influenza vaccine in infants and young children</article-title>. 
<source>N Engl J Med</source>
<year>2007</year>; <volume>356</volume>:<fpage>685</fpage>&#x02013;<lpage>696</lpage>.
<pub-id pub-id-type="pmid">17301299</pub-id></mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4">
<string-name>
<surname>Belshe</surname>
<given-names>RB</given-names>
</string-name>, 
<string-name>
<surname>Gruber</surname>
<given-names>WC</given-names>
</string-name>, 
<string-name>
<surname>Mendelman</surname>
<given-names>PM</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Efficacy of vaccination with live attenuated, cold&#x02010;adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine</article-title>. 
<source>J Pediatr</source>
<year>2000</year>; <volume>136</volume>:<fpage>168</fpage>&#x02013;<lpage>175</lpage>.
<pub-id pub-id-type="pmid">10657821</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5">
<string-name>
<surname>Belshe</surname>
<given-names>RB</given-names>
</string-name>, 
<string-name>
<surname>Mendelman</surname>
<given-names>PM</given-names>
</string-name>, 
<string-name>
<surname>Treanor</surname>
<given-names>J</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>The efficacy of live attenuated, cold&#x02010;adapted, trivalent, intranasal influenzavirus vaccine in children</article-title>. 
<source>N Engl J Med</source>
<year>1998</year>; <volume>338</volume>:<fpage>1405</fpage>&#x02013;<lpage>1412</lpage>.
<pub-id pub-id-type="pmid">9580647</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6">
<string-name>
<surname>Bracco</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Farhat</surname>
<given-names>CK</given-names>
</string-name>, 
<string-name>
<surname>Tregnaghi</surname>
<given-names>MW</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Efficacy and safety of one and two doses of live attenuated influenza vaccine in vaccine&#x02010;naive children</article-title>. 
<source>Pediatr Infect Dis J</source>
<year>2009</year>; <volume>28</volume>:<fpage>365</fpage>&#x02013;<lpage>371</lpage>.
<pub-id pub-id-type="pmid">19395948</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7">
<string-name>
<surname>Fleming</surname>
<given-names>DM</given-names>
</string-name>, 
<string-name>
<surname>Crovari</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Wahn</surname>
<given-names>U</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Comparison of the efficacy and safety of live attenuated cold&#x02010;adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma</article-title>. 
<source>Pediatr Infect Dis J</source>
<year>2006</year>; <volume>25</volume>:<fpage>860</fpage>&#x02013;<lpage>869</lpage>.
<pub-id pub-id-type="pmid">17006278</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8">
<string-name>
<surname>Forrest</surname>
<given-names>BD</given-names>
</string-name>, 
<string-name>
<surname>Pride</surname>
<given-names>MW</given-names>
</string-name>, 
<string-name>
<surname>Dunning</surname>
<given-names>AJ</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Correlation of cellular immune responses with protection against culture&#x02010;confirmed influenza virus in young children</article-title>. 
<source>Clin Vaccine Immunol</source>
<year>2008</year>; <volume>15</volume>:<fpage>1042</fpage>&#x02013;<lpage>1053</lpage>.
<pub-id pub-id-type="pmid">18448618</pub-id></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="miscellaneous" id="cit9">
<string-name>
<surname>Lum</surname>
<given-names>LCS</given-names>
</string-name>, 
<string-name>
<surname>Forrest</surname>
<given-names>BD</given-names>
</string-name>, <collab collab-type="authors">The LAIV Concomitant Vaccine Study Group</collab>
. 
<article-title>Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children</article-title>. 
<article-title>Vaccine</article-title>
<year>2009</year>
DOI:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2009.11.054">10.1016/j.vaccine.2009.11.054</ext-link>.
</mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal" id="cit10">
<string-name>
<surname>Tam</surname>
<given-names>JS</given-names>
</string-name>, 
<string-name>
<surname>Capeding</surname>
<given-names>MR</given-names>
</string-name>, 
<string-name>
<surname>Lum</surname>
<given-names>LC</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Efficacy and safety of a live attenuated, cold&#x02010;adapted influenza vaccine, trivalent against culture&#x02010;confirmed influenza in young children in Asia</article-title>. 
<source>Pediatr Infect Dis J</source>
<year>2007</year>; <volume>26</volume>:<fpage>619</fpage>&#x02013;<lpage>628</lpage>.
<pub-id pub-id-type="pmid">17596805</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11">
<string-name>
<surname>Vesikari</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Fleming</surname>
<given-names>DM</given-names>
</string-name>, 
<string-name>
<surname>Aristegui</surname>
<given-names>JF</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Safety, efficacy, and effectiveness of cold&#x02010;adapted influenza vaccine&#x02010;trivalent against community&#x02010;acquired, culture&#x02010;confirmed influenza in young children attending day care</article-title>. 
<source>Pediatrics</source>
<year>2006</year>; <volume>118</volume>:<fpage>2298</fpage>&#x02013;<lpage>2312</lpage>.
<pub-id pub-id-type="pmid">17142512</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="miscellaneous" id="cit12">
<string-name>
<surname>Hawksworth</surname>
<given-names>AW</given-names>
</string-name>, 
<string-name>
<surname>Russell</surname>
<given-names>KL</given-names>
</string-name>, 
<string-name>
<surname>Faix</surname>
<given-names>DJ</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Effectiveness of the 2006&#x02010;2007 influenza vaccine: data from US military basic training centers [Abstract P725]</article-title>. 6th Meeting of the Options for Control of Influenza Diseases, 17&#x02013;23 June
<year>2007</year>, Toronto, ON, Canada.
</mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="miscellaneous" id="cit13">
<string-name>
<surname>Hawksworth</surname>
<given-names>AW</given-names>
</string-name>, 
<string-name>
<surname>Russell</surname>
<given-names>KL</given-names>
</string-name>, 
<string-name>
<surname>Strickler</surname>
<given-names>JK</given-names>
</string-name>, 
<string-name>
<surname>Gaydos</surname>
<given-names>JC</given-names>
</string-name>, 
<string-name>
<surname>Malone</surname>
<given-names>JL</given-names>
</string-name>, 
<string-name>
<surname>Ryan</surname>
<given-names>MAK</given-names>
</string-name>. 
<article-title>Effectiveness of the 2004&#x02013;2005 influenza vaccine: data from US military basic training centers [Abstract 1012]</article-title>. 43rd Annual Meeting of IDSA, 6&#x02013;9 October, <year>2005</year>, San Francisco, CA.
</mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14">
<string-name>
<surname>Treanor</surname>
<given-names>JJ</given-names>
</string-name>, 
<string-name>
<surname>Kotloff</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Betts</surname>
<given-names>RF</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Evaluation of trivalent, live, cold&#x02010;adapted (CAIV&#x02010;T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild&#x02010;type influenza A (H1N1), A (H3N2), and B viruses</article-title>. 
<source>Vaccine</source>
<year>1999</year>; <volume>18</volume>:<fpage>899</fpage>&#x02013;<lpage>906</lpage>.
<pub-id pub-id-type="pmid">10580204</pub-id></mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15">
<string-name>
<surname>Ohmit</surname>
<given-names>SE</given-names>
</string-name>, 
<string-name>
<surname>Victor</surname>
<given-names>JC</given-names>
</string-name>, 
<string-name>
<surname>Rotthoff</surname>
<given-names>JR</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines</article-title>. 
<source>N Engl J Med</source>
<year>2006</year>; <volume>355</volume>:<fpage>2513</fpage>&#x02013;<lpage>2522</lpage>.
<pub-id pub-id-type="pmid">17167134</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="journal" id="cit16">
<string-name>
<surname>Strickler</surname>
<given-names>JK</given-names>
</string-name>, 
<string-name>
<surname>Hawksworth</surname>
<given-names>AW</given-names>
</string-name>, 
<string-name>
<surname>Myers</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Irvine</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Ryan</surname>
<given-names>MA</given-names>
</string-name>, 
<string-name>
<surname>Russell</surname>
<given-names>KL</given-names>
</string-name>. 
<article-title>Influenza vaccine effectiveness among US military basic trainees, 2005&#x02010;06 season</article-title>. 
<source>Emerg Infect Dis</source>
<year>2007</year>; <volume>13</volume>:<fpage>617</fpage>&#x02013;<lpage>619</lpage>.
<pub-id pub-id-type="pmid">17553281</pub-id></mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="journal" id="cit17">
<string-name>
<surname>Monto</surname>
<given-names>AS</given-names>
</string-name>, 
<string-name>
<surname>Ohmit</surname>
<given-names>SE</given-names>
</string-name>, 
<string-name>
<surname>Petrie</surname>
<given-names>JG</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Comparative efficacy of inactivated and live attenuated influenza vaccines</article-title>. 
<source>N Engl J Med</source>
<year>2009</year>; <volume>361</volume>:<fpage>1260</fpage>&#x02013;<lpage>1267</lpage>.
<pub-id pub-id-type="pmid">19776407</pub-id></mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="journal" id="cit18">
<string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, 
<string-name>
<surname>Tobler</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Roayaei</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Eick</surname>
<given-names>A</given-names>
</string-name>. 
<article-title>Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel</article-title>. 
<source>JAMA</source>
<year>2009</year>; <volume>301</volume>:<fpage>945</fpage>&#x02013;<lpage>953</lpage>.
<pub-id pub-id-type="pmid">19255113</pub-id></mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19">
<string-name>
<surname>Eick</surname>
<given-names>AA</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, 
<string-name>
<surname>Hughes</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Ford</surname>
<given-names>SM</given-names>
</string-name>, 
<string-name>
<surname>Tobler</surname>
<given-names>SK</given-names>
</string-name>. 
<article-title>Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members</article-title>. 
<source>Vaccine</source>
<year>2009</year>; <volume>27</volume>:<fpage>3568</fpage>&#x02013;<lpage>3575</lpage>.
<pub-id pub-id-type="pmid">19464536</pub-id></mixed-citation></ref><ref id="b20"><label>20</label><mixed-citation publication-type="book" id="cit20">
Data on File. Gaithersburg, MD: <publisher-name>MedImmune, Inc</publisher-name>, <year>2006</year>.
</mixed-citation></ref><ref id="b21"><label>21</label><mixed-citation publication-type="journal" id="cit21">
<string-name>
<surname>Piedra</surname>
<given-names>PA</given-names>
</string-name>, 
<string-name>
<surname>Gaglani</surname>
<given-names>MJ</given-names>
</string-name>, 
<string-name>
<surname>Kozinetz</surname>
<given-names>CA</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Trivalent live attenuated intranasal influenza vaccine administered during the 2003&#x02010;2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children</article-title>. 
<source>Pediatrics</source>
<year>2007</year>; <volume>120</volume>:<fpage>e553</fpage>&#x02013;<lpage>e564</lpage>.
<pub-id pub-id-type="pmid">17698577</pub-id></mixed-citation></ref><ref id="b22"><label>22</label><mixed-citation publication-type="journal" id="cit22">
<string-name>
<surname>Belshe</surname>
<given-names>RB</given-names>
</string-name>, 
<string-name>
<surname>Gruber</surname>
<given-names>WC</given-names>
</string-name>, 
<string-name>
<surname>Mendelman</surname>
<given-names>PM</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Correlates of immune protection induced by live, attenuated, cold&#x02010;adapted, trivalent, intranasal influenza virus vaccine</article-title>. 
<source>J Infect Dis</source>
<year>2000</year>; <volume>181</volume>:<fpage>1133</fpage>&#x02013;<lpage>1137</lpage>.
<pub-id pub-id-type="pmid">10720541</pub-id></mixed-citation></ref><ref id="b23"><label>23</label><mixed-citation publication-type="journal" id="cit23">
<string-name>
<surname>Block</surname>
<given-names>SL</given-names>
</string-name>, 
<string-name>
<surname>Reisinger</surname>
<given-names>KS</given-names>
</string-name>, 
<string-name>
<surname>Hultquist</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Walker</surname>
<given-names>RE</given-names>
</string-name>. 
<article-title>Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects</article-title>. 
<source>Antimicrob Agents Chemother</source>
<year>2007</year>; <volume>51</volume>:<fpage>4001</fpage>&#x02013;<lpage>4008</lpage>.
<pub-id pub-id-type="pmid">17724151</pub-id></mixed-citation></ref><ref id="b24"><label>24</label><mixed-citation publication-type="journal" id="cit24">
<string-name>
<surname>Block</surname>
<given-names>SL</given-names>
</string-name>, 
<string-name>
<surname>Yogev</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Hayden</surname>
<given-names>FG</given-names>
</string-name>, 
<string-name>
<surname>Ambrose</surname>
<given-names>CS</given-names>
</string-name>, 
<string-name>
<surname>Zeng</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Walker</surname>
<given-names>RE</given-names>
</string-name>. 
<article-title>Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5&#x02013;49&#x02003;years of age</article-title>. 
<source>Vaccine</source>
<year>2008</year>; <volume>26</volume>:<fpage>4940</fpage>&#x02013;<lpage>4946</lpage>.
<pub-id pub-id-type="pmid">18662737</pub-id></mixed-citation></ref><ref id="b25"><label>25</label><mixed-citation publication-type="journal" id="cit25">
<string-name>
<surname>Hobson</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Curry</surname>
<given-names>RL</given-names>
</string-name>, 
<string-name>
<surname>Beare</surname>
<given-names>AS</given-names>
</string-name>, 
<string-name>
<surname>Ward&#x02010;Gardner</surname>
<given-names>A</given-names>
</string-name>. 
<article-title>The role of serum haemagglutination&#x02010;inhibiting antibody in protection against challenge infection with influenza A2 and B viruses</article-title>. 
<source>J Hyg (Lond)</source>
<year>1972</year>; <volume>70</volume>:<fpage>767</fpage>&#x02013;<lpage>777</lpage>.
<pub-id pub-id-type="pmid">4509641</pub-id></mixed-citation></ref><ref id="b26"><label>26</label><mixed-citation publication-type="journal" id="cit26">
<string-name>
<surname>Potter</surname>
<given-names>CW</given-names>
</string-name>, 
<string-name>
<surname>Oxford</surname>
<given-names>JS</given-names>
</string-name>. 
<article-title>Determinants of immunity to influenza infection in man</article-title>. 
<source>Br Med Bull</source>
<year>1979</year>; <volume>35</volume>:<fpage>69</fpage>&#x02013;<lpage>75</lpage>.
<pub-id pub-id-type="pmid">367490</pub-id></mixed-citation></ref><ref id="b27"><label>27</label><mixed-citation publication-type="journal" id="cit27">
<string-name>
<surname>Potter</surname>
<given-names>CW</given-names>
</string-name>, 
<string-name>
<surname>Jennings</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Nicholson</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Tyrrell</surname>
<given-names>DA</given-names>
</string-name>, 
<string-name>
<surname>Dickinson</surname>
<given-names>KG</given-names>
</string-name>. 
<article-title>Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines</article-title>. 
<source>J Hyg (Lond)</source>
<year>1977</year>; <volume>79</volume>:<fpage>321</fpage>&#x02013;<lpage>332</lpage>.
<pub-id pub-id-type="pmid">270523</pub-id></mixed-citation></ref><ref id="b28"><label>28</label><mixed-citation publication-type="journal" id="cit28">
<string-name>
<surname>Nichol</surname>
<given-names>KL</given-names>
</string-name>, 
<string-name>
<surname>Mendelman</surname>
<given-names>PM</given-names>
</string-name>, 
<string-name>
<surname>Mallon</surname>
<given-names>KP</given-names>
</string-name>
<italic>
et&#x000a0;al.
</italic>
<article-title>Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial</article-title>. 
<source>JAMA</source>
<year>1999</year>; <volume>282</volume>:<fpage>137</fpage>&#x02013;<lpage>144</lpage>.
<pub-id pub-id-type="pmid">10411194</pub-id></mixed-citation></ref></ref-list></back></article>